Fusion Pharmaceuticals Inc. (FUSN): Price and Financial Metrics

Fusion Pharmaceuticals Inc. (FUSN): $21.31

0.05 (-0.23%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

F

FUSN Price/Volume Stats

Current price $21.31 52-week high $21.55
Prev. close $21.36 52-week low $2.31
Day low $21.30 Volume 527,800
Day high $21.40 Avg. volume 2,144,227
50-day MA $14.83 Dividend yield N/A
200-day MA $7.32 Market Cap 1.80B

FUSN Stock Price Chart Interactive Chart >


Fusion Pharmaceuticals Inc. (FUSN) Company Bio


Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops GMP manufacturing of radiopharmaceuticals for the diagnosis and treatment of disease. The company was founded by John Vaillant and is headquartered in Hamilton, Canada.


FUSN Latest News Stream


Event/Time News Detail
Loading, please wait...

FUSN Latest Social Stream


Loading social stream, please wait...

View Full FUSN Social Stream

Latest FUSN News From Around the Web

Below are the latest news stories about FUSION PHARMACEUTICALS INC that investors may wish to consider to help them evaluate FUSN as an investment opportunity.

Why Fusion Pharmaceuticals (FUSN) Stock Was Up 14% on Wednesday

Fusion Pharmaceuticals (FUSN) surges to a new record level 52-week high after analysts at Raymond James upgraded its rating following the buyout announcements for two comparable companies.

Yahoo | December 28, 2023

Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned

With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole remaining clinical-stage player with a robust supply chain. In September, Oppenheimer initiated coverage on Fusion Pharmaceuticals, citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies. Most recently, Bristol Myers Squibb & Co (NYSE: BM

Yahoo | December 27, 2023

Gracell downgrade, Fusion upgrade: Wall Street's top analyst calls

Gracell downgrade, Fusion upgrade: Wall Street's top analyst calls

Yahoo | December 27, 2023

4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow

Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.

Yahoo | December 20, 2023

Wall Street Analysts Predict a 149.52% Upside in Fusion Pharmaceuticals Inc. (FUSN): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 149.5% in Fusion Pharmaceuticals Inc. (FUSN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | December 13, 2023

Read More 'FUSN' Stories Here

FUSN Price Returns

1-mo 113.31%
3-mo N/A
6-mo 379.95%
1-year 424.88%
3-year 144.66%
5-year N/A
YTD 121.75%
2023 205.08%
2022 -24.46%
2021 -64.51%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!